Overview

TransCelerate held its first annual Realization Summit which provided attendees with an opportunity to learn about initiative solutions and delivery, engage in one-on-one conversations with initiative experts, as well as discussions with industry representatives from the entire clinical trial ecosystem.

Three Tracks

The two-day event featured dedicated time to visit interactive learning tables hosted by active TransCelerate initiatives and 3 Tracks Focused on Mature Solutions Ready for Adoption:

  • Track 1: Site Qualification & Training, Investigator Registry & Shared Investigator Platform
  • ­Track 2: Risk Based Monitoring and Quality Management System
  • Track 3: Clinical Data Standards, Common Protocol Template, and Comparator Network

First Panel

In addition, TransCelerate Oversight Committee Member Craig Lipset (Pfizer) moderated a panel and Q&A session with leaders from TransCelerate Member Companies who reviewed the history of TransCelerate, along with the benefits and achievements and what the future holds for TransCelerate. Our panel included:

  • Andy Lee, Senior Vice President and Head of Global Clinical Trial Operations at Merck, TransCelerate Corporate Treasurer
  • Lynn Marks, Senior Clinical Advisor for the Infectious Diseases Therapy Area Unit, GSK, TransCelerate Corporate Secretary & Oversight Committee Chair
  • Peter Ronco, Vice President, Global Clinical Operations at BMS, TransCelerate Board Member
  • Paul Stoeffels, Chief Scientific officer and Worldwide Chairman of Pharmaceuticals at Johnson & Johnson, TransCelerate Board Member

Second Panel

A highlight of the Realization Summit was the second day panel moderated by our CEO Dalvir Gill that included industry experts representing various Clinical trial stakeholders. The conversation focused on collaboration in the industry both current and future state.  Panel members featured:

  • Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA)
  • Christine Pierre, President of Society for Clinical Research Sites (SCRS)
  • David Simmons, Chairman & CEO of PPD
  • Pam Tenaerts, Executive Director, Clinical Trials Transformation Initiative (CTTI)